known functional polymorphisms in the OPRD1 and OPRK1 genes, a tSNP approach was used to provide coverage of the two genes of interest. Consistent with this data-driven approach and with the absence of functional data on these markers, no a-priori hypotheses were advanced for the effects of any specific tSNP. Instead, these analyses tested interactions between OPRK1 and OPRD1 genotypes and medication (naltrexone versus placebo) on the stimulant, sedative, and craving effects produced by alcohol administration. This exploratory study seeks to extend naltrexone pharmacogenetics to OPRD1 and OPRK1 genes as they may contribute to the individual differences observed in naltrexone response.
